Filing Analysis
Profound Medical Corp. issued a press release announcing the introduction of its new real-time interventional MRI Software. This is a regulatory disclosure under Item 7.01 regarding non-filed information.
📋 Key Facts
- Company announced the introduction of new real-time interventional MRI Software on August 17, 2026.
- The announcement was made via a press release furnished as Exhibit 99.1.
- The filing is made under Item 7.01 (Regulation FD Disclosure).
Profound Medical Corp. issued an 8-K to announce the launch of 'Let’s Huddle', a new patient advocacy initiative via press release.
📋 Key Facts
- Company launched a patient advocacy initiative titled 'Let’s Huddle'.
- The announcement was made via a press release dated August 13, 2026.
- Information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Profound Medical Corp. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2026, and provided a general business update via press release.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
Profound Medical Corp. issued a press release regarding new data from the Level 1 post-market CAPTAIN randomized controlled trial, which compares the TULSA Procedure with robotic radical prostatectomy.
📋 Key Facts
- Company released clinical data from the Level 1 post-market CAPTAIN randomized controlled trial on July 24, 2026.
- The study compares the efficacy/safety of the TULSA Procedure against robotic radical prostatectomy.
- Information was furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Profound Medical Corp. announced the upcoming release of its second quarter financial results and a scheduled conference call to discuss business developments.
📋 Key Facts
- Q2 financial results are scheduled to be released after market close on August 6, 2026.
- A conference call to review results and discuss business developments is set for August 6, 2026, at 4:30 p.m. ET.
- The announcement was made via a press release furnished as Exhibit 99.1.
Profound Medical Corp. issued an 8-K to announce that its TULSA Procedure™ will be featured in several presentations at the upcoming Society of Robotic Surgery Annual Meeting scheduled for July 23-26, 2026.
📋 Key Facts
- Company's TULSA Procedure™ to be highlighted at the Society of Robotic Surgery Annual Meeting.
- Meeting location: Fort Lauderdale, FL.
- Event dates: July 23-26, 2026.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure) and is furnished, not filed.
Profound Medical Corp. reported the results of its Annual General and Special Meeting held on May 13, 2026. Shareholders elected eight directors, reappointed PricewaterhouseCoopers LLP as auditors, and approved unallocated units under the company's long-term incentive plan.
🚩 Red Flags
- Significant shareholder opposition to the Long-Term Incentive Plan, with 36.078% voting against the resolution.
- Notable 'Withheld' votes for certain directors, specifically Arthur Rosenthal (21.001% withheld) and Brian Ellacott (18.446% withheld).
📋 Key Facts
- The meeting was held on May 13, 2026, with results filed on May 15, 2026.
- Eight director nominees were elected, including CEO Arun Menawat (90.257% for).
- PricewaterhouseCoopers LLP was reappointed as the auditor with 99.497% support.
- The resolution to approve unallocated restricted share units (RSUs) and deferred share units (DSUs) passed with 63.922% of the vote.
Profound Medical Corp. announced that its TULSA Procedure™ will be featured in four oral presentations at the American Urological Association’s (AUA) Annual Meeting on May 16, 2026.
📋 Key Facts
- The TULSA Procedure™ will be highlighted in four oral presentations.
- The presentations will take place at the AUA Annual Meeting in Washington, DC.
- The event is scheduled for May 16, 2026.
- The information was furnished under Item 7.01 (Regulation FD Disclosure).
Profound Medical Corp. announced its financial results for the first quarter ended March 31, 2026, and provided a business update. The information was furnished via a press release as part of a routine quarterly reporting cycle.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026.
- The report was filed on May 7, 2026, under Item 2.02 Results of Operations and Financial Condition.
- A press release (Exhibit 99.1) was furnished alongside the filing.
- The filing includes a signature from Rashed Dewan, Chief Financial Officer.
Profound Medical Corp. announced it will release its first quarter 2026 financial results after market close on May 7, 2026. The company will host a conference call and webcast at 4:30 p.m. ET that same day to discuss the results and business developments.
📋 Key Facts
- Earnings release date for Q1 2026 is set for May 7, 2026.
- Conference call scheduled for May 7, 2026, at 4:30 p.m. Eastern Time.
- The announcement was made via a press release furnished as Exhibit 99.1.
- The filing is made under Item 7.01 (Regulation FD Disclosure).
Profound Medical Corp. announced it will present a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026.
📋 Key Facts
- The presentation is scheduled for April 22, 2026, at 10:00 a.m. Eastern Time.
- The event will take place at the Metro Toronto Convention Centre and will be available via live broadcast.
- The announcement was formally disclosed under Item 7.01 (Regulation FD Disclosure).
Profound Medical Corp. announced that its TULSA Procedure™ will be featured in several presentations at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The event is scheduled to take place in Toronto, ON, from April 11-15, 2026.
📋 Key Facts
- The Company's interventional MRI TULSA Procedure™ will be highlighted at the 2026 SIR Annual Scientific Meeting.
- The meeting is scheduled for April 11-15, 2026, in Toronto, Ontario.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure) and includes a press release as Exhibit 99.1.
- The information in the filing is furnished and not deemed 'filed' for regulatory liability purposes.
Profound Medical Corp. announced that Texas Prostate, led by Dr. James Cochran, has completed its 100th TULSA Procedure™ at Dallas Medical Center. The announcement highlights the continued clinical adoption and utilization of the company's TULSA technology in a real-world medical setting.
📋 Key Facts
- Texas Prostate achieved its 100th TULSA Procedure™ milestone.
- The procedures were performed at Dallas Medical Center’s state-of-the-art MRI suite.
- The announcement was made via a press release dated March 27, 2026.
- The lead physician for these procedures is Dr. James Cochran.
Profound Medical Corp. announced that its CAPTAIN trial, comparing the MRI-guided TULSA Procedure™ to robotic radical prostatectomy, has successfully met its primary safety endpoint.
📋 Key Facts
- The CAPTAIN trial is a head-to-head study comparing TULSA Procedure™ against robotic radical prostatectomy.
- The primary safety endpoint of the trial was successfully met as of March 13, 2026.
- The announcement was made via a press release furnished under Item 7.01 (Regulation FD).
- The TULSA Procedure is the company's core MRI-guided therapeutic technology.
Profound Medical Corp. announced the resignation of director Kris Shah and the immediate appointment of Frank Baylis to the Board of Directors effective March 5, 2026. The transition appears to be a routine board refresh as there were no reported disagreements.
📋 Key Facts
- Kris Shah resigned from the Board of Directors effective March 5, 2026.
- Frank Baylis was appointed to fill the vacancy effective immediately.
- The resignation was not the result of any disagreement with the Company.
- Mr. Baylis will receive an annual retainer of $50,000 and is eligible for annual equity awards.
- Mr. Baylis will serve until the 2026 annual meeting of stockholders.
Profound Medical Corp. announced an upcoming investor conference call scheduled for March 13, 2026, to discuss clinical outcomes from its CAPTAIN trial. The announcement was furnished via a press release under Regulation FD disclosure requirements.
📋 Key Facts
- Conference call scheduled for March 13, 2026, at 11:30 a.m. ET
- The call will specifically address clinical outcomes of the Company's CAPTAIN trial
- The filing was made under Item 7.01 (Regulation FD Disclosure)
- Rashed Dewan, CFO, signed the report on March 9, 2026
Profound Medical Corp. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing serves as a formal vehicle to furnish the earnings press release and provide a business update.
📋 Key Facts
- Announced Q4 and FY 2025 financial results on March 5, 2026.
- Information furnished under Item 2.02 (Results of Operations and Financial Condition).
- Includes Exhibit 99.1, the press release detailing performance.
- Signed by CFO Rashed Dewan.
Profound Medical Corp. announced the upcoming release of its fourth quarter and full year 2025 financial results, scheduled for March 5, 2026.
📋 Key Facts
- Financial results for Q4 and FY 2025 to be released after market close on March 5, 2026.
- A conference call and webcast to discuss results is scheduled for March 5, 2026, at 4:30 p.m. ET.
Profound Medical Corp. issued a press release announcing that it received the 2025–2026 Mount Logan Award from INOVAIT for its TULSA Procedure used in treating prostate disease.
📋 Key Facts
- The Company was honored by INOVAIT, a Canadian national network for image-guided therapy and AI commercialization.
- The award (Mount Logan Award) recognizes the TULSA Procedure for prostate disease.
- The announcement was made via press release on February 12, 2026.
Profound Medical Corp. issued a press release announcing that PRO FAMILIA Specialist Hospital in Poland has completed its 500th Sonalleve® procedure. This is a routine operational update provided under Regulation FD.
📋 Key Facts
- PRO FAMILIA Specialist Hospital (Rzeszów, Poland) reached a milestone of 500 Sonalleve® procedures.
- The announcement was made via press release on February 5, 2026.
- Information is furnished under Item 7.01 and is not considered 'filed' for liability purposes.
Profound Medical Corp. filed an 8-K to announce upcoming investor events via a press release. This is a routine regulatory filing used to furnish non-public information to the market in compliance with Regulation FD.
📋 Key Facts
- The company issued a press release on January 27, 2026, regarding upcoming investor events.
- The filing was signed by CFO Rashed Dewan.
- Information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Profound Medical Corp. issued a press release announcing that Mount Sinai Hospital has successfully treated its first prostate cancer patient using the company's TULSA-PRO® system.
📋 Key Facts
- Mount Sinai Hospital performed its first treatment using the TULSA-PRO® system on or before January 15, 2026.
- The announcement was made via a press release furnished under Item 7.01 (Regulation FD Disclosure).
- The filing includes Exhibit 99.1 containing the full press release.
Profound Medical Corp. issued a press release under Regulation FD to announce its TULSA-PRO® installed base metrics as of year-end 2025.
📋 Key Facts
- As of December 31, 2025, the Company's TULSA-PRO® installed base stood at 78 systems.
- The announcement was made via a press release dated January 12, 2026.
Profound Medical Corp. announced that The Johns Hopkins Hospital has successfully treated its first non-clinical-trial prostate cancer patient using the company's TULSA-PRO® system.
📋 Key Facts
- Date of event: January 6, 2026
- Milestone: First non-clinical-trial patient treatment at The Johns Hopkins Hospital
- Technology used: TULSA-PRO® system
- The announcement was made via press release furnished under Item 7.01.
Profound Medical Corp. completed a private placement of 921,428 common shares to Canadian investors on December 30, 2025. The offering raised $6.45 million at a price of $7.00 per share.
🚩 Red Flags
- Equity dilution: Issuance of 921,428 new shares will dilute existing shareholders.
- Regulation S offering: The sale was conducted outside the US, which is common for micro-caps needing quick liquidity but limits immediate domestic investor participation.
📋 Key Facts
- Aggregate gross proceeds: $6.45 million
- Number of shares issued: 921,428 common shares
- Offering price: $7.00 per share
- Investors: Certain Canadian investors (non-U.S. persons)
- Transaction type: Private placement under Regulation S
- Registration intent: Company intends to file a registration statement for resale within four months of closing.
Profound Medical Corp. has entered into a registered direct offering of 5,142,870 common shares at $7.00 per share, aiming to raise approximately $36 million in gross proceeds. Additionally, the company is pursuing a private placement of up to 571,428 shares for an additional $4 million from Canadian purchasers.
🚩 Red Flags
- Significant dilution: The issuance of over 5 million shares at $7.00 per share represents a substantial increase in the float.
- 60-day trading restriction: The company agreed to restrictions on the issuance or sale of common shares for 60 days following the closing.
📋 Key Facts
- Registered direct offering of 5,142,870 common shares at $7.00 per share.
- Aggregate gross proceeds estimated at $36 million before fees and expenses.
- Expected closing date for the offering is on or about December 22, 2025.
- Private placement of up to 571,428 common shares at $7.00 per share (up to $4 million) targeting Canadian purchasers.
- Konik Capital Partners, LLC engaged as placement agent with a 5.0% cash fee plus expense reimbursement.
- Proceeds intended for sales/marketing expansion, working capital, R&D, and strategic transactions.
Profound Medical Corp. issued an 8-K to announce the launch of its TULSA-AI® Volume Reduction module at the upcoming Radiological Society of North America (RSNA) meeting.
📋 Key Facts
- Company will launch TULSA-AI® Volume Reduction module.
- Launch event is scheduled for the RSNA meeting in Chicago.
- Meeting dates: November 30, 2025, through December 4, 2025.
Profound Medical Corp. has entered into an exclusive distribution and supply agreement for its TULSA-PRO® system in Australia and New Zealand with Getz Healthcare.
📋 Key Facts
- Agreement date: November 12, 2025
- Counterparty: Getz Healthcare
- Scope: Exclusive distribution and supply of the TULSA-PRO® system
- Territory: Australia and New Zealand
Profound Medical Corp. has entered into an exclusive distribution and supply agreement for its TULSA-PRO® and Sonalleve® technologies in Saudi Arabia with Al Faisaliah Medical Systems Co.
📋 Key Facts
- Agreement date: November 11, 2025
- Counterparty: Al Faisaliah Medical Systems Co.
- Scope: Exclusive distribution and supply agreement for TULSA-PRO® and Sonalleve® technologies in Saudi Arabia
- Filing Item: 7.01 (Regulation FD Disclosure)
Profound Medical Corp. announced that it has regained exclusive distribution rights for its TULSA-PRO® technology in Canada from Knight Therapeutics Inc.
📋 Key Facts
- Date of event: November 10, 2025
- Company regained exclusive distribution rights for TULSA-PRO® in Canada
- The previous distributor was Knight Therapeutics Inc.
- Information furnished under Item 7.01 is not considered 'filed' for purposes of Section 18 of the Exchange Act
Profound Medical Corp. issued an 8-K to announce preliminary unaudited financial results for the third quarter ended September 30, 2025, and provided a general business update.
📋 Key Facts
- Report date: October 7, 2025
- Reporting period: Three months ended September 30, 2025
- Nature of disclosure: Preliminary unaudited financial results and business update
- The filing includes Exhibit 99.1 (Press Release)
Profound Medical Corp. filed an 8-K to announce its unaudited financial results and a business update for the three and six months ended June 30, 2025.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Three and six months ended June 30, 2025
- The filing includes unaudited financial results and a business update via press release (Exhibit 99.1)
- Signed by Rashed Dewan, Chief Financial Officer
Profound Medical Corp. announced the appointment of former NFL safety Leonard Wheeler as a Global Ambassador for its TULSA-PRO® technology.
📋 Key Facts
- Appointment date: June 4, 2025
- Individual: Leonard Wheeler (former NFL safety)
- Role: Global Ambassador for TULSA-PRO®
- Filing type: Regulation FD Disclosure (Item 7.01)
Profound Medical Corp. held its 2025 Annual General and Special Meeting of Shareholders on May 14, 2025. The meeting resulted in the election of six directors, the appointment of PricewaterhouseCoopers LLP as auditors, and approval of unallocated options under the company's share option plan.
🚩 Red Flags
- Significant opposition to unallocated options (31.73% against) suggests potential shareholder dissatisfaction regarding dilution or compensation structures.
📋 Key Facts
- Annual General Meeting held on May 14, 2025.
- Six director nominees elected: Arun Menawat (94.5%), Brian Ellacott (93.7%), Cynthia Lavoie (97.0%), Murielle Lortie (95.8%), Arthur Rosenthal (92.4%), and Kris Shah (93.6%).
- PricewaterhouseCoopers LLP appointed as auditors with 99.49% approval.
- Unallocated options under the share option plan approved by shareholders with 68.27% in favor.
Profound Medical Corp. filed an 8-K to announce its unaudited financial results for the first quarter ended March 31, 2025, and provided a general business update via press release.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Three months ended March 31, 2025
- Content includes unaudited financial results and a business update
- The information in Item 2.02 is furnished rather than filed for liability purposes under Section 18 of the Exchange Act.
Profound Medical Corp. issued a press release regarding peri-operative CAPTAIN trial data presented at the American Urological Association (AUA) Annual Meeting.
📋 Key Facts
- The company released clinical trial data from the CAPTAIN study on April 29, 2025.
- Data was presented at the American Urological Association’s (AUA) Annual Meeting.
- The information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Profound Medical Corp. is providing notice of a corporate update presentation to be delivered at the American Urological Association (AUA) Annual Meeting on April 28, 2025. The filing includes investor presentation slides as an exhibit.
📋 Key Facts
- Company will present a corporate update at the AUA Annual Meeting on April 28, 2025.
- The presentation will be available via live and archived webcast on the Company's website.
- Investor presentation slides are provided as Exhibit 99.1.
Profound Medical Corp. filed an 8-K to concurrently file its Notice of 2025 Annual and Special Meeting of Shareholders and Management Information Circular with Canadian regulatory authorities.
📋 Key Facts
- The filing is a routine disclosure of the 2025 Annual and Special Meeting of Shareholders materials.
- Management Information Circular dated April 22, 2025, was attached as Exhibit 99.1.
- Company operates as a foreign private issuer preparing information in accordance with Canadian law.
Profound Medical Corp. has announced that previously issued financial statements for the first three quarters of 2024 should no longer be relied upon due to a revenue overstatement error identified during the transition from IFRS to U.S. GAAP. Additionally, the company entered into an amended credit agreement with CIBC involving a revolving line of credit.
🚩 Red Flags
- Restatement of previously issued financial statements (Item 4.02).
- Revenue overstatement error identified during GAAP transition.
- Strict cash covenants requiring a minimum of $7,500,000 in unrestricted cash if EBITDA is negative.
📋 Key Facts
- Revenue was overstated by $472,000 in Q1 2024 due to accounting errors identified during transition to U.S. GAAP.
- The error affects financial statements for the three months ended March 31, June 30, and September 30, 2024.
- Entered into an amended and restated credit agreement with CIBC on March 3, 2025.
- Revolving line of credit matures March 3, 2027, with a current limit of $10,000,000.
- Option to increase revolving commitment by $5,000,000 if trailing 12-month revenue exceeds $15,000,000 within 18 months.
- Credit agreement includes a cash covenant requiring unrestricted cash to be the greater of $7.5M or EBITDA (if EBITDA is negative).
Profound Medical Corp. issued an 8-K to announce the release of preliminary unaudited revenues for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: January 8, 2025
- Subject matter: Preliminary unaudited revenues for Q4 and FY 2024
- The filing includes a press release as Exhibit 99.1